ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,346.99
-0.11%
US Tech 100
18,488.00
-0.25%
Dow Jones
38,798.99
-0.22%
Brent Oil
79.395
0.00%
Bitcoin
69,376.32
0.06%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Stoke Therapeutics Inc (STOK) Quote

Stoke Therapeutics Inc

Stoke Therapeutics Inc (STOK)

NASDAQ
14.86
-0.35
(-2.30%)
Closed June 08 4:00PM
Delayed by 15 minutes
14.86
0.00
(0.00%)
After Hours: 4:00PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
14.86
Bid
14.27
Ask
15.59
Volume
381,583
14.55 Day's Range 15.1875
3.35 52 Week Range 16.69
Market Cap
663.109M
Previous Close
15.21
Open
14.76
Last Trade
11500
@
14.86
(priorref)
Last Trade Time
Financial Volume
$ 5,647,789
VWAP
14.8009
Average Volume (3m)
1,539,509
Shares Outstanding
44,653,782
Dividend Yield
-
PE Ratio
-6.33
Earnings Per Share (EPS)
-2.34
Revenue
8.78M
Net Profit
-104.7M

About Stoke Therapeutics Inc

Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively... Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.stoketherapeutics.com
Headquarters
Dover, Delaware, USA
Founded
1970
Stoke Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker STOK. The last closing price for Stoke Therapeutics was $15.21. Over the last year, Stoke Therapeutics shares have traded in a share price range of $ 3.35 to $ 16.69.

Stoke Therapeutics currently has 44,653,782 shares outstanding. The market capitalization of Stoke Therapeutics is $663.11 million. Stoke Therapeutics has a price to earnings ratio (PE ratio) of -6.33.

STOK Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities

10 hours ago
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

10 hours ago
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

10 hours ago
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

10 hours ago
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

10 hours ago
Edgar (US Regulatory)

Form 8-K - Current report

June 06 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 05 2024
Edgar (US Regulatory)

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today...

June 03 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

May 22 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

May 22 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.966.9064748201413.916.6913.985054515.30814699CS
42.7222.405271828712.1416.6911.0178199214.48319226CS
128.38129.3209876546.4816.695.6153950912.33040159CS
2610.59248.0093676814.2716.694.0984099011.35066889CS
521.7113.003802281413.1516.693.3557966110.06389548CS
156-22.99-60.739762219337.8541.63.3536225412.8322466CS
260-12.35-45.387725101127.2171.583.3528444517.47039495CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CLEUChina Liberal Education Holdings Ltd
$ 3.1505
(55.97%)
18.32M
HUDAHudson Acquisition I Corporation
$ 16.6999
(52.51%)
636.05k
VEROVenus Concept Inc
$ 0.893101
(52.22%)
69.53M
HRYUHanryu Holdings Inc
$ 0.5047
(40.55%)
2.83M
HUDAUHudson Acquisition I Corporation
$ 15.77
(30.22%)
3.77k
DSYBig Tree Cloud Holdings Limited
 1.9091
(-74.67%)
413.98k
BMEABiomea Fusion Inc
$ 4.14
(-63.27%)
11.88M
NBSTWNewbury Street Acquisition Corporation
$ 0.0374
(-32.00%)
174.15k
DHACUDigital Health Acquisition Corporation
$ 15.90
(-30.20%)
2.1k
SCNIScinai Immunotherapeutics Ltd
$ 2.97
(-28.41%)
717.99k
FFIEFaraday Future Intelligent Electric Inc
$ 0.602
(10.66%)
419.77M
PRSTPresto Technologies Inc
$ 0.09
(18.58%)
325.8M
SQQQProShares UltraPro Short QQQ
$ 9.32
(0.32%)
120.35M
CRKNCrown Electrokinetics Corporation
$ 0.0902
(3.20%)
119.61M
GERNGeron Corp
$ 4.60
(18.25%)
98.94M

STOK Discussion

View Posts
Zardiw Zardiw 2 months ago
$STOK Chart from #DDAmanda - #1 Stock Screener :

Scans are preset. Push a Button. Find Winners Early:



Z
👍️0
TimeFades TimeFades 2 months ago
Choppy day shoulda just stuck with my morning short
👍️0
TimeFades TimeFades 2 months ago
Got bullish again and covered
👍️0
TimeFades TimeFades 2 months ago
Short from 12s
👍️0
Invest-in-America Invest-in-America 2 months ago
STOK: "Stoke Therapeutics (NASDAQ:STOK) stock shot up 70% in post-market trading Monday after the company reported positive results from studies for its drug STK-001 in the treatment of children and adolescents with Dravet syndrome, a genetic form of epilepsy. The biotech company said data from two Phase 1/2a studies and two open label extension, or OLE, studies showed “clinically meaningful effects” that included “substantial and durable reductions in convulsive seizure frequency."
https://seekingalpha.com/news/4083468-stoke-stock-soars-post-market-on-epilepsy-drug-data

Dravet Syndrome is an extremely RARE disease in the USA. And the above news does NOT specify nor suggest that STOK's (potential) treatment for Dravet Syndrome will or might have any applications for treatment of EPILEPSY at all. (Be very CAREFUL about news like the above.)
👍️0

Your Recent History

NASDAQ
STOK
Stoke Therapeutics
NASDAQ
UNB
Union Bankshares
USOTC
CNUTF
Canadian Utilities (PK)
LSE
33YM
Stand.chart.23
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved